Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. (Q54387375)

29 May 2018

title

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. (English)

1 reference

29 May 2018

1 reference

1 reference

Jiake He

1

1 reference

29 May 2018

Zhixia Qiu

2

1 reference

29 May 2018

Ning Li

3

1 reference

29 May 2018

Yang Yu

4

1 reference

29 May 2018

Yang Lu

5

1 reference

29 May 2018

Deen Han

6

1 reference

29 May 2018

Tingting Li

7

1 reference

29 May 2018

Di Zhao

8

1 reference

29 May 2018

Wei Sun

9

1 reference

29 May 2018

Fang Fang

10

1 reference

29 May 2018

Jianheng Zheng

11

1 reference

29 May 2018

Hongwei Fan

12

1 reference

29 May 2018

Xijing Chen

13

1 reference

29 May 2018

publication date

17 February 2011

1 reference

29 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

29 May 2018

volume

67

1 reference

29 May 2018

page(s)

701-707

1 reference

29 May 2018

issue

7

1 reference

29 May 2018

https://scigraph.springernature.com/pub.10.1007/s00228-011-0994-7

exact match

0 references

cites work

Clinical pharmacokinetics and pharmacodynamics of repaglinide

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Role of OATP transporters in the disposition of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

SLCO1B1 polymorphism and oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Rifampin decreases the plasma concentrations and effects of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

Genetic polymorphisms of CYP3A4: CYP3A4⁎18 allele is found in five healthy Malaysian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0994-7

The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma

21 January 2018

1 reference

12 December 2020

Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry

1 reference

12 December 2020

A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane

1 reference

12 December 2020

Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.

1 reference

12 December 2020

10.1007/S00228-011-0994-7

Identifiers

DOI

1 reference

29 May 2018

PubMed ID

21327909

1 reference

29 May 2018